Author

T. J. Herron

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Monteiro da Rocha· 2 shared E. N. Jimenez-Vazquez· 2 shared G. Guerrero-Serna· 2 shared A. J. Cuttita· 1 shared A. Macias· 1 shared D. E. Michele· 1 shared D. Ponce-Balbuena· 1 shared F. M. Cruz· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

A. Monteiro da Rocha

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

SNTA1 GeneRescues Ion Channel Function in Cardiomyocytes Derived from Induced Pluripotent Stem Cells Reprogrammed from Muscular Dystrophy Patients with Arrhythmias

J. Jalife, E. N. Jimenez-Vazquez, M. Arad, A. Macias, M. L. Vera-Pedrosa, F. M. Cruz, A. J. Cuttita, A. Monteiro da Rocha, T. J. Herron, D. Ponce-Balbuena, G. Guerrero-Serna, O. Binah, D. E. Michele

This study shows that iPSC-CMs from DMD patients with arrhythmias have NaV1.5-Kir2.1 channelosome dysfunction, which can be rescued by 1-syntrophin.

bioRxiv · Jan 25, 2022 · PreprintCell Biology

From atoms to cells: bridging the gap between potency, efficacy, and safety of small molecules directed at a membrane protein

R. Aguayo-Ortiz, J. Creech, E. N. Jimenez-Vazquez, G. Guerrero-Serna, N. Wang, A. Monteiro da Rocha, T. J. Herron, L. M. Espinoza-Fonseca

This study combines computational and experimental methods to evaluate drug potency, efficacy, and safety for targeting membrane proteins, using SERCA2a as a model.

bioRxiv · Mar 19, 2021Pharmacology & Toxicology